• 1
    Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J. and Pinsky, M. R., Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001. 29: 13031310.
  • 2
    Remick, D. G., Pathophysiology of sepsis. Am. J. Pathol. 2007. 170: 14351444.
  • 3
    Bone, R. C., Grodzin, C. J. and Balk, R. A., Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997. 112: 235243.
  • 4
    Hotchkiss, R. S. and Karl, I. E., The pathophysiology and treatment of sepsis. N. Engl. J. Med. 2003. 348: 138150.
  • 5
    Rittirsch, D., Flierl, M. A. and Ward, P. A., Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 2008. 8: 776787.
  • 6
    Bone, R. C., Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care Med. 1996. 24: 11251128.
  • 7
    Docke, W. D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H. D. et al., Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 1997. 3: 678681.
  • 8
    Hotchkiss, R. S., Coopersmith, C. M., McDunn, J. E. and Ferguson, T. A., The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 2009. 15: 496497.
  • 9
    Heidecke, C. D., Hensler, T., Weighardt, H., Zantl, N., Wagner, H., Siewert, J. R. and Holzmann, B., Selective defects of T lymphocyte function in patients with lethal intra-abdominal infection. Am. J. Surg. 1999. 178: 288292.
  • 10
    Beutler, B., TNF, immunity and inflammatory disease: lessons of the past decade. J. Invest. Med. 1995. 43: 227.
  • 11
    Natanson, C., Hoffman, W. D., Suffredini, A. F., Eichacker, P. Q. and Danner, R. L., Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann. Intern. Med. 1994. 120: 771783.
  • 12
    Remick, D. G., Call, D. R., Ebong, S. J., Newcomb, D. E., Nybom, P., Nemzek, J. A. and Bolgos, G. E., Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit. Care Med. 2001. 29: 473481.
  • 13
    Fisher, C. J., Jr., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E. et al., Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 1996. 334: 16971702.
  • 14
    Randow, F., Syrbe, U., Meisel, C., Krausch, D., Zuckermann, H., Platzer, C. and Volk, H. D., Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J. Exp. Med. 1995. 181: 18871892.
  • 15
    Kasten, K. R., Tschop, J., Adediran, S. G., Hildeman, D. A. and Caldwell, C. C., T cells are potent early mediators of the host response to sepsis. Shock 2010. 34: 327336.
  • 16
    Martignoni, A., Tschop, J., Goetzman, H. S., Choi, L. G., Reid, M. D., Johannigman, J. A., Lentsch, A. B. et al., CD4-expressing cells are early mediators of the innate immune system during sepsis. Shock 2008. 29: 591597.
  • 17
    Kasten, K. R., Tschop, J., Goetzman, H. S., England, L. G., Dattilo, J. R., Cave, C. M., Seitz, A. P. et al., T-cell activation differentially mediates the host response to sepsis. Shock 2010. 34: 377383.
  • 18
    Reim, D., Westenfelder, K., Kaiser-Moore, S., Schlautkotter, S., Holzmann, B. and Weighardt, H., Role of T cells for cytokine production and outcome in a model of acute septic peritonitis. Shock 2009. 31: 245250.
  • 19
    Thiel, M., Caldwell, C. C., Kreth, S., Kuboki, S., Chen, P., Smith, P., Ohta, A. et al., Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS One 2007. 2: e853.
  • 20
    Unsinger, J., McGlynn, M., Kasten, K. R., Hoekzema, A. S., Watanabe, E., Muenzer, J. T., McDonough, J. S. et al., IL-7 promotes T-cell viability, trafficking, and functionality and improves survival in sepsis. J. Immunol. 2010. 184: 37683779.
  • 21
    van Schaik, S. M. and Abbas, A. K., Role of T cells in a murine model of Escherichia coli sepsis. Eur. J. Immunol. 2007. 37: 31013110.
  • 22
    Herman, A., Kappler, J. W., Marrack, P. and Pullen, A. M., Superantigens: mechanism of T-cell stimulation and role in immune responses. Annu. Rev. Immunol. 1991. 9: 745772.
  • 23
    Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. and Hill, A. M., M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 2000. 164: 61666173.
  • 24
    Martinez, F. O., Helming, L. and Gordon, S., Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009. 27: 451483.
  • 25
    Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A. and Locati, M., The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004. 25: 677686.
  • 26
    Giatromanolaki, A., Sivridis, E., Maltezos, E., Papazoglou, D., Simopoulos, C., Gatter, K. C., Harris, A. L. et al., Hypoxia-inducible factor 1-alpha and 2-alpha overexpression in inflammatory bowel disease. J. Clin. Pathol. 2003. 56: 209213.
  • 27
    Wenger, R. H., Rolfs, A., Kvietikova, P., Spielmann, P., Zimmermann, D. R. and Gassmann, M., The mouse gene for hypoxia-inducible factor-1. Genomic organization, expression and characterization of an alternative first exon and 5′ flanking sequence. Eur. J. Biochem. 1997. 246: 155165.
  • 28
    Wenger, R. H., Rolfs, A., Spielmann, P., Zimmermann, D. R. and Gassmann, M., Mouse hypoxia-inducible factor-1 is encoded by two different mRNA isoforms : expression from a tissue-specific and a housekeeping-type promoter. Blood 1998. 91: 34713480.
  • 29
    Semenza, G. L., Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr. Opin. Genet. Dev. 1998. 8: 588594.
  • 30
    Lukashev, D., Caldwell, C., Ohta, A., Chen, P. and Sitkovsky, M., Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes. J. Biol. Chem. 2001. 276: 4875448763.
  • 31
    Lukashev, D., Klebanov, B., Kojima, H., Grinberg, A., Ohta, A., Berenfeld, L., Wenger, R. H. et al., Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J. Immunol. 2006. 177: 49624965.
  • 32
    Ramanathan, M., Luo, W., Csoka, B., Hasko, G., Lukashev, D., Sitkovsky, M. V. and Leibovich, S. J., Differential regulation of HIF-1alpha isoforms in murine macrophages by TLR4 and adenosine A(2A) receptor agonists. J. Leukoc. Biol. 2009. 86: 681689.
  • 33
    Srinivasan, S., Bolick, D. T., Lukashev, D., Lappas, C., Sitkovsky, M., Lynch, K. R. and Hedrick, C. C., Sphingosine-1-phosphate reduces CD4+ T-cell activation in type 1 diabetes through regulation of hypoxia-inducible factor short isoform I.1 and CD69. Diabetes 2008. 57: 484493.
  • 34
    Sitkovsky, M. and Lukashev, D., Regulation of immune cells by local-tissue oxygen tension: HIF1alpha and adenosine receptors. Nat. Rev. Immunol. 2005. 5: 712721.
  • 35
    Lukashev, D. and Sitkovsky, M., Preferential expression of the novel alternative isoform I.3 of hypoxia-inducible factor 1alpha in activated human T lymphocytes. Hum. Immunol. 2008. 69: 421425.
  • 36
    Buras, J. A., Holzmann, B. and Sitkovsky, M., Animal models of sepsis: setting the stage. Nat. Rev. Drug Discov. 2005. 4: 854865.
  • 37
    Belikoff, B. G., Hatfield, S., Georgiev, P., Ohta, A., Lukashev, D., Buras, J. A., Remick, D. G. et al., A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J. Immunol. 2011. 186: 24442453.
  • 38
    Ryan, H. E., Lo, J. and Johnson, R. S., HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998. 17: 30053015.
  • 39
    Dang, E.V., Barbi, J., Yang, H.Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z. et al., Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011. 146: 772784.
  • 40
    Haskó, G., Csóka, B., Koscsó, B., Chandra, R., Pacher, P., Thompson, L.F., Deitch, E. A. et al., Ecto-5′-nucleotidase (CD73) decreases mortality and organ injury in sepsis. J. Immunol. 2011. 187: 42564267.
  • 41
    Reutershan, J., Vollmer, I., Stark, S., Wagner, R., Ngamsri, K. C. and Eltzschig, H. K. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 2009. 23: 473482.
  • 42
    Lee, P. P., Fitzpatrick, D. R., Beard, C., Jessup, H. K., Lehar, S., Makar, K. W., Perez-Melgosa, M. et al., A critical role for Dnmt1 and DNA methylation in T-cell development, function, and survival. Immunity 2001. 15: 763774.
  • 43
    Saraiva, M., O'Garra, A., The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010. 10: 170181.
  • 44
    Ito, S., Ansari, P., Sakatsume, M., Dickensheets, H., Vazquez, N., Donnelly, R. P., Larner, A. C. et al., Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999. 93: 14561463.
  • 45
    Schopf, L. R., Hoffmann, K. F., Cheever, A. W., Urban, J. F., Jr. and Wynn, T. A., IL-10 is critical for host resistance and survival during gastrointestinal helminth infection. J. Immunol. 2002. 168: 23832392.
  • 46
    Schroder, M., Meisel, C., Buhl, K., Profanter, N., Sievert, N., Volk, H. D. and Grutz, G., Different modes of IL-10 and TGF-beta to inhibit cytokine-dependent IFN-gamma production: consequences for reversal of lipopolysaccharide desensitization. J. Immunol. 2003. 170: 52605267.
  • 47
    Quiding-Jarbrink, M., Raghavan, S. and Sundquist, M., Enhanced M1 macrophage polarization in human Helicobacter pylori-associated atrophic gastritis and in vaccinated mice. PLoS One 2010. 5: e15018.
  • 48
    Ben-Shoshan, J., Afek, A., Maysel-Auslender, S., Barzelay, A., Rubinstein, A., Keren, G. and George, J., HIF-1alpha overexpression and experimental murine atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009. 29: 665670.
  • 49
    Shah, Y. M., Ito, S., Morimura, K., Chen, C., Yim, S. H., Haase, V. H. and Gonzalez, F. J., Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology 2008. 134: 20362048.
  • 50
    Takeda, N., O'Dea, E. L., Doedens, A., Kim, J. W., Weidemann, A., Stockmann, C., Asagiri, M. et al., Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev. 2010. 24: 491501.
  • 51
    Cramer, T., Yamanishi, Y., Clausen, B. E., Forster, I., Pawlinski, R., Mackman, N., Haase, V. H. et al., HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003. 112: 645657.
  • 52
    Feinman, R., Deitch, E. A., Watkins, A. C., Abungu, B., Colorado, I., Kannan, K. B., Sheth, S. U. et al., HIF-1 mediates pathogenic inflammatory responses to intestinal ischemia-reperfusion injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2010. 299: G833G843.
  • 53
    Roiniotis, J., Dinh, H., Masendycz, P., Turner, A., Elsegood, C. L., Scholz, G. M. and Hamilton, J. A., Hypoxia prolongs monocyte/macrophage survival and enhanced glycolysis is associated with their maturation under aerobic conditions. J. Immunol. 2009. 182: 79747981.
  • 54
    Lukashev, D., Ohta, A., Apasov, S., Chen, J. F. and Sitkovsky, M., Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J. Immunol. 2004. 173: 2124.